TRACON Pharmaceuticals Announces Poster Presentation at the 2021 AACR Virtual Annual Meeting
March 23, 2021 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, March 23, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference
March 09, 2021 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Announces Appointment of Lisa Johnson-Pratt, M.D., to its Board of Directors
March 08, 2021 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
March 02, 2021 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
February 25, 2021 16:03 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON to Report Fourth Quarter and Full Year 2020 Financial Results and Company Highlights on February 25, 2021
February 18, 2021 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China for Priority Review
January 19, 2021 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
January 06, 2021 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China that was Submitted by its Corporate Partners Alphamab Oncology and 3D Medicines
December 30, 2020 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Announces $5.0 Million Registered Direct Offering
December 29, 2020 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Dec. 29, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...